Fourteen Everolimus Lies Disclosed

Self-administered questionnaires collected data on patient characteristics, fracture risk factors, previous fractures, AOM use, and health status. Data were analyzed from women who used the same class of AOM continuously over 3 survey years and had data available http://www.selleckchem.com/products/azd9291.html on fracture occurrence. Multivariable logistic regression was used to identify independent predictors of treatment failure. Data from 26,918 women were available, of whom 5550 were on AOM. During follow-up, 73 of 5550 women in the AOM group (1.3%) and 123 of 21,368 in the non-AOM group (0.6%) reported occurrence of two or more fractures. The following variables were associated with treatment failure: lower Short Form 36 Health Survey (SF-36) score (physical function and vitality) at baseline, higher Fracture Risk Assessment Tool (FRAX) score, falls in the past 12 months, selected comorbid conditions, prior fracture, current use of glucocorticoids, need of arms to assist to standing, and unexplained weight loss ��10 lb (��4.5?kg). Three variables remained predictive of treatment failure after multivariable analysis: http://www.selleck.cn/products/Everolimus(RAD001).html worse SF-36 vitality score (odds ratio [OR] per 10-point increase, 0.85; 95% confidence interval [CI], 0.76�C0.95; p?=?0.004); two or more falls in the past year (OR, 2.40; 95% CI, 1.34�C4.29; p?=?0.011), and prior fracture (OR, 2.93; 95% CI, 1.81�C4.75; p? http://www.selleckchem.com/products/ch5424802.html and 40% for hip fractures, depending on the drug, with some of the antiresorptives only showing efficacy against vertebral fracture.[2-8] Concern has been raised, however, over a subgroup of women who experience multiple fractures while on AOM.[9] An expert group representing the International Osteoporosis Foundation (IOF) has designated the problem of two or more episodes of fracture occurring while taking therapies used to reduce the risk of fracture as ��treatment failure.��[10] The Global Longitudinal Study of Osteoporosis in Women (GLOW) is a prospective cohort study of postmenopausal women, in which data on osteoporosis, fractures, and treatments for osteoporosis are collected, along with other health information.